Cover ImageSALE
市場調查報告書

骨關節炎的幹細胞治療:開發平台分析報告

Stem Cell Therapy for Osteoarthritis - A Pipeline Analysis Report

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 570478
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
骨關節炎的幹細胞治療:開發平台分析報告 Stem Cell Therapy for Osteoarthritis - A Pipeline Analysis Report
出版日期: 2017年10月13日 內容資訊: 英文 70 Pages
簡介

預測全球骨關節炎市場在2014∼2019年將以年複合成長率8.55%擴大。對該疾病的認識度提升,診斷率的改善,高齡化,肥胖病例的增加等促進了市場的成長。

本報告提供骨關節炎的幹細胞治療市場現狀與未來發展預測,彙整市場情況,打入市場的主要企業等資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 調查方法

第4章 骨關節炎的幹細胞治療:概要

  • 簡介

第5章 法律規章當局

  • 美國
  • 歐洲
  • 日本
  • 澳洲
  • 中國

第6章 開發平台環境

第7章 比較分析

  • 後期分子(第三階段)
  • 中期分子(第二階段,1/2相)
  • 早期分子(第一階段,前臨床)
  • 惰性分子

第8章 適應分析

第9章 不同治療評估

第10章 各給藥途徑評估

第11章 各階段各給藥途徑評估

第12章 主要企業

  • 活躍企業:類別和參數
  • 附錄
  • 簡稱清單

第13章 附錄

圖表

目錄
Product Code: IRTNTR15693

Stem cell therapy for osteoarthritis: An insight

The stem cell therapy for osteoarthritis pipeline analysis report includes ongoing clinical and non-clinical trends in the global stem cell therapy for osteoarthritis. Majority of the pipeline therapeutics are in early stages of development. There is no cure for the disease, but treatments are available to manage the symptoms. A long-lasting and less-frequent dose can impact overall osteoarthritis market.

The global osteoarthritis market is expected to grow at a CAGR of 8.55% over the period of 2014-2019. The expected growth is because of increasing awareness of osteoarthritis and increasing diagnosis rates, rising older population, and increasing cases of obesity. Osteoarthritis is directly related to obesity, with approximately 37% of osteoarthritis patients suffering from obesity.

Covered in this report

The report covers the present scenario and the growth prospects of the stem cell therapy for osteoarthritis. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

Technavio's Stem Cell Therapy for Osteoarthritis - A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.

Major companies

  • Mesoblast
  • Regeneus
  • U.S. Stem Cell
  • Anterogen
  • Asterias Biotherapeutics

Key questions answered in this report

  • How will the market evolve during the forecast period?
  • What are the major parameters impacting the market?
  • What are the key market trends?
  • What are the challenges to market growth?
  • Who are the key companies in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: STEM CELL THERAPY FOR OSTEOARTHRITIS: AN INSIGHT

  • Introduction

PART 05: MAJOR REGULATORY AUTHORITIES

  • US
  • Europe
  • Japan
  • Australia
  • China

PART 06: PIPELINE LANDSCAPE

PART 07: COMPARATIVE ANALYSIS

  • Late-stage molecule (Phase III)
  • Mid-stage molecules (Phase II and Phase I/II)
  • Early-stage molecules (Phase I and pre-clinical)
  • Inactive molecules

PART 08: INDICATION ANALYSIS

PART 09: THERAPEUTIC ASSESSMENT BY THERAPY

  • Therapeutic assessment based on therapy

PART 10: THERAPEUTIC ASSESSMENT BY ROA

  • Therapeutic assessment based on RoA

PART 11: THERAPEUTIC ASSESSMENT BY STAGE AND ROA

  • Therapeutic assessment based on RoA in various stages of development

PART 12: KEY COMPANIES

  • Active companies: Category and parameters

APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Drug approval process by US FDA
  • Exhibit 02: Pipeline molecules by vendors
  • Exhibit 03: Pipeline landscape
  • Exhibit 04: Pipeline molecules in different developmental stages 2017
  • Exhibit 05: Percentage of pipeline molecules in different developmental stages 2017
  • Exhibit 06: Overview: GID SVF
  • Exhibit 07: Clinical trials description of autologous adipose-derived SVF cells
  • Exhibit 08: Overview: ReJoin
  • Exhibit 09: Clinical trials description of ReJoin (mesenchymal progenitor cells)
  • Exhibit 10: Overview: Autologous regenerative cell therapy
  • Exhibit 11: Clinical trials description of autologous regenerative cell therapy
  • Exhibit 12: Overview: MSB-CAR001
  • Exhibit 13: Clinical trials description of MSB-CAR001
  • Exhibit 14: Overview: Stempeucel
  • Exhibit 15: Clinical trials description of Stempeucel osteoarthritis
  • Exhibit 16: Overview: Stemchymal
  • Exhibit 17: Clinical trials description of Stemchymal
  • Exhibit 18: Overview: Elixcyte
  • Exhibit 19: Clinical trials description of Elixcyte
  • Exhibit 20: Overview: AlloJoin
  • Exhibit 21: Clinical trials description of AlloJoin
  • Exhibit 22: Overview: Human Umbilical Cord MSCs
  • Exhibit 23: Clinical trials description of Human umbilical cord MSCs
  • Exhibit 24: Overview: Progenza
  • Exhibit 25: Clinical trials description of Progenza
  • Exhibit 26: Overview: Adipose-derived stromal cells
  • Exhibit 27: Clinical trials description of Adipose-derived stromal cells
  • Exhibit 28: Overview: ALLO-ASC-OA
  • Exhibit 29: Overview: GRNCHND1
  • Exhibit 30: Overview: Stem cell therapy for osteoarthritis
  • Exhibit 31: Overview: Allogeneic mesenchymal stem cell candidate
  • Exhibit 32: Inactive molecules 2017
  • Exhibit 33: Analysis by indication
  • Exhibit 34: Assessment of stem cell therapy for osteoarthritis by therapy
  • Exhibit 35: Assessment of stem cell therapy for osteoarthritis by RoA
  • Exhibit 36: Assessment of stem cell therapy for osteoarthritis by stage and RoA
  • Exhibit 37: Active companies: Category and parameters 2017
  • Exhibit 38: Segmentation of companies 2017
  • Exhibit 39: Overview: Anterogen 2017
  • Exhibit 40: Overview: Asterias Biotherapeutics 2017
  • Exhibit 41: Overview: Cellular Biomedicine Group 2017
  • Exhibit 42: Overview: Mesoblast 2017
  • Exhibit 43: Overview: Regeneus 2017
  • Exhibit 44: Overview: OrthoCyte* 2017
  • Exhibit 45: Overview: Shenzhen Hornetcorn Bio-technology 2017
  • Exhibit 46: Overview: Steminent Biotherapeutics 2017
  • Exhibit 47: Overview: Stempeutics Research 2017
  • Exhibit 48: Overview: The GID Group 2017
  • Exhibit 49: Overview: UnicoCell Biomed 2017
  • Exhibit 50: Overview: U.S. Stem Cell 2017
  • Exhibit 51: Overview: VivaTech International 2017
  • Exhibit 52: Overview: Xintela 2017
Back to Top